製品番号: HY-N2593

Isorhapontigenin

4 Cited Publications

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.82%
CAS 番号: 32507-66-7
分子式: C₁₅H₁₄O₄
分子量:258.27

保管条件:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Isorhapontigenin 構造式

CAS 番号: 32507-66-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- Parmacokinetics
- 体内実験
化学情報
Publications (4)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

CPT-1A

MMP-2

PPARα

PPARγ

FOXO1

IL-6

NF-κB アイソフォーム固有の製品をすべて表示 :

PI3K アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

MMP アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Platelet	IC₅₀	1.85 μM Compound: Isorhapontigenin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 5 mins followed by ADP addition and measured after 5 mins Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 5 mins followed by ADP addition and measured after 5 mins	[PMID: 34731765]

体外実験

Isorhapontigenin (1.25-40 μM; 24 h) induces autophagy in a dose-dependent manner in UMUC3, T24T, and HeLa cells, and this autophagy contributes to its inhibition of anchorage-independent growth of UMUC3 cells^[1].
Isorhapontigenin (2.5-10 μM; 12-24 h) increases SESN2 transcription via a JUN-dependent mechanism, which is required for autophagy induction and inhibition of anchorage-independent growth in UMUC3 cells^[1].
Isorhapontigenin (10 μM; 12 h pre-APAP treatment, 24 h post-APAP treatment) attenuates APAP-induced FAO dysregulation in AML12 cells by upregulating PPAR-α/PGC-1α/CPT-1A signaling^[2].
Isorhapontigenin (1-100 μM; 1 h pre-incubation + 24 h stimulation, 1 h pre-incubation + 10-60 min stimulation) inhibits IL-6 and CXCL8 release from primary human airway epithelial cells and A549 cells, with IC₅₀ values for IL-6 of 17.3-19.7 μM, and suppresses NF-κB, AP-1, and PI3K/Akt/FoxO3A signaling pathways^[3].
Isorhapontigenin (1-100 μM; 1 h pre-incubation + 30 min stimulation) concentration-dependently reduces intracellular ROS levels in IL-1β-stimulated A549 cells^[3].
Isorhapontigenin (5-15 μM; 12 h pretreatment + 12 h LPS stimulation) exerts anti-inflammatory and antioxidant effects on LPS-challenged RAW264.7 cells by reducing pro-inflammatory mediator and ROS production^[4].
Isorhapontigenin (15 μM; 0-24 h direct treatment, 12 h pretreatment + 12 h LPS stimulation) activates the Nrf2 pathway in RAW264.7 cells, and its anti-inflammatory/antioxidant effects depend on Nrf2 activation^[4].
Isorhapontigenin (25 μM; 6 days) promotes adipocyte differentiation, enhances insulin sensitivity, and reduces lipolysis in 3T3-L1 preadipocytes by increasing PPARγ activity and expression^[5].
Isorhapontigenin (25 μM; 0-12 h) increases PPARγ activity and stability in 3T3-L1 cells by reducing inhibitory phosphorylation and decelerating proteasomal degradation^[5].
Isorhapontigenin (10-20 μM; 24 h) specifically inhibits invasion of UMUC3 and T24T human invasive bladder cancer cells, respectively, without affecting migration^[6].
Isorhapontigenin (2.5-20 μM; 6-18 h) induces dose- and time-dependent upregulation of FOXO1 protein expression in UMUC3 and T24T human invasive bladder cancer cells^[6].
Isorhapontigenin (2.5-20 μM; 3-9 h) upregulates foxo1 mRNA expression at the transcriptional level in UMUC3 and T24T human invasive bladder cancer cells^[6].
Isorhapontigenin (10 μM; 6-18 h) enhances FOXO1 promoter activity in a time-dependent manner in UMUC3 human invasive bladder cancer cells^[6].
Isorhapontigenin (2.5-10 μM; 12 h) inhibits STAT1 phosphorylation at Tyr701 in a dose-dependent manner in UMUC3 human invasive bladder cancer cells^[6].
Isorhapontigenin (2.5-20 μM; 18 h) inhibits dose-dependent MMP-2 protein expression in UMUC3 and T24T human invasive bladder cancer cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Autophagy Assay^[1]

Cell Line:

UMUC3, T24T, HeLa
Concentration:

1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

24 h
Result:

Caused a dose-dependent increase in LC3-I to LC3-II conversion in UMUC3, T24T, and HeLa cells. Increased the percentage of GFP-LC3 puncta-positive cells and the number of puncta per cell in a dose-dependent manner in GFP-LC3-transfected UMUC3 cells.

Western Blot Analysis^[1]

Cell Line:

UMUC3
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

24 h
Result:

Increased SESN2 and BECN1 expression at 2.5-10 μM in UMUC3 cells. Saw its induced LC3-II formation unaffected by BECN1 knockdown in UMUC3 cells. Had its LC3-II formation significantly attenuated in SESN2 knockdown UMUC3 cells. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when SESN2 was knocked down.

Western Blot Analysis^[1]

Cell Line:

UMUC3
Concentration:

5 μM, 10 μM
Incubation Time:

6 h, 12 h, 24 h
Result:

Increased MAPK8 phosphorylation in a dose-dependent manner. Had its induced JUN phosphorylation, SESN2 induction, LC3-II formation, SESN2 mRNA expression, and SESN2 promoter activity blocked when MAPK8 was knocked down. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when MAPK8 was knocked down.

Cell Differentiation Assay^[5]

Cell Line:

3T3-L1 preadipocytes
Concentration:

25 μM
Incubation Time:

6 days (differentiation)
Result:

Promoted lipid accumulation (quantified by Oil Red O staining optical density at 490 nm). Significantly increased mRNA and protein expression of PPARγ target genes (CEBPα, FAS, FABP4, GLUT4) and PPARγ itself. Enhanced insulin-stimulated glucose uptake (1.5-fold over basal). Reduced mRNA and protein levels of hormone-sensitive lipase (HSL).

Cell Invasion Assay^[6]

Cell Line:

UMUC3, T24T human invasive bladder cancer cells
Concentration:

10 μM (UMUC3 cells); 20 μM (T24T cells)
Incubation Time:

24 h (UMUC3, T24T cells)
Result:

Reduced relative invasion rate of UMUC3 cells by 63.1% and T24T cells by 61.2% compared to vehicle control; did not affect cell migration under the same conditions.

Western Blot Analysis^[6]

Cell Line:

UMUC3, T24T human invasive bladder cancer cells
Concentration:

2.5-10 μM (UMUC3 cells, dose-response); 10-20 μM (T24T cells, dose-response); 10 μM (UMUC3 cells, time-course)
Incubation Time:

12 h (UMUC3, T24T cells, dose-response); 6-18 h (UMUC3 cells, time-course)
Result:

Induced FOXO1 protein expression in a dose-dependent manner in UMUC3 and T24T cells; caused a gradual increase in FOXO1 protein level.

RT-PCR^[6]

Cell Line:

UMUC3, T24T human invasive bladder cancer cells
Concentration:

2.5-10 μM (UMUC3 cells, dose-response); 10 μM (UMUC3 cells, time-course); 10-20 μM (T24T cells, dose-response)
Incubation Time:

6 h (UMUC3, T24T cells, dose-response); 3-9 h (UMUC3 cells, time-course)
Result:

Upregulated endogenous foxo1 mRNA expression in a dose-dependent manner in UMUC3 and T24T cells, and in a time-dependent manner in UMUC3 cells; did not affect exogenous flag-foxo1 mRNA expression.

Western Blot Analysis^[6]

Cell Line:

UMUC3 human invasive bladder cancer cells
Concentration:

2.5-10 μM
Incubation Time:

12 h
Result:

Dramatically inhibited STAT1 phosphorylation at Tyr701 in a dose-dependent manner without affecting total STAT1 protein expression.

Western Blot Analysis^[6]

Cell Line:

UMUC3, T24T human invasive bladder cancer cells
Concentration:

2.5-10 μM (UMUC3 cells); 10-20 μM (T24T cells)
Incubation Time:

18 h (UMUC3, T24T cells)
Result:

Profoundly inhibited MMP-2 protein expression in a dose-dependent manner in both UMUC3 and T24T cells.

RT-PCR^[6]

Cell Line:

T24T human invasive bladder cancer cells
Concentration:

10-20 μM
Incubation Time:

18 h
Result:

Attenuated MMP-2 mRNA level in a dose-dependent manner; did not affect MMP-9 mRNA level.

Parmacokinetics

Species	Dose	Route	MRT_0-last	C_max	T_max	Bioavailability	V_d	CL
Rat^[3]	7.74 mg/kg	i.v.	14.1 min	/	/	/	830 mL/kg	89.2 ± 6.3 mL/min/kg
Rat^[3]	154.8 mg/kg	p.o.	268 min	9.9 μg/mL	30-60 min	47.2 %	/	/

体内実験

Isorhapontigenin (150 mg/kg; daily) markedly inhibits xenograft tumor growth in nude mice injected with T24T cells^[1].
Isorhapontigenin (25-50 mg/kg; i.g. once of once daily for 3 consecutive days) alleviates acetaminophen-induced liver injury in mice by reducing apoptosis, inflammation, oxidative stress, and restoring fatty acid oxidation, with 25 and 50 mg/kg doses showing efficacy^[2].
Isorhapontigenin (51.6 mg/kg; p.o.; daily; 7 days) effectively ameliorates LPS-induced acute lung injury in mice by reducing inflammation and oxidative stress^[4].
Isorhapontigenin (25 mg/kg; i.p.; daily; 5 weeks) ameliorates type 2 diabetes in db/db mice by improving glucose and insulin homeostasis, enhancing insulin sensitivity, and modulating adipose tissue function via PPARγ regulation^[5].
Isorhapontigenin (150 mg/kg/day; drinking water; daily; 20 weeks) inhibits N-Butyl-N-(4-hydroxybutyl)nitrosamine (BBN) (HY-W755252)-induced invasive bladder cancer formation in C57BL/6J mice, with 16.7% of treated mice developing high-grade muscle-invasive disease versus 100% in BBN-only controls^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 6-8 weeks old; Acetaminophen-induced liver injury model)^[2]
Dosage:

25 mg/kg; 50 mg/kg
Administration:

i.g. (once, 1 hour after acetaminophen); i.g. (once daily for 3 consecutive days, acetaminophen on day 3); i.g. (once, 1 hour before acetaminophen); i.g. (once, 3 hours after acetaminophen)
Result:

Significantly reduced serum ALT, AST, and LDH levels, centrilobular necrosis area, TUNEL-positive cells, C-PARP expression, serum TNF-α and IL-6 levels, liver MDA levels, and increased liver CAT levels at 25 and 50 mg/kg (post-treatment) compared to acetaminophen alone; reduced lipid accumulation (Oil Red O and BODIPY staining), serum and liver TG levels, increased liver ATP content and FAO activity, and upregulated PPAR-α, PGC-1α, and CPT-1A protein expression at 50 mg/kg (pre-treatment).

Animal Model:

C57BL/6 (male, 6-8 weeks old, 20-25 g, LPS-challenged)^[4]
Dosage:

51.6 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Reduced LPS-induced lung injury score, myeloperoxidase (MPO) activity in lung tissues, lung wet/dry weight ratio, and protein concentration in bronchoalveolar lavage fluid (BALF); suppressed LPS-induced increases in BALF concentrations of IL-1β, IL-6, and TNF-α; inhibited p-NF-κB p65 expression and IκB degradation in lung tissues; reduced malondialdehyde (MDA) formation in lung tissues; restored superoxide dismutase (SOD) and glutathione (GSH) activities in lung tissues.

Animal Model:

db/db mice (male, 8 weeks old at treatment start, genetically diabetic model)^[5]
Dosage:

25 mg/kg
Administration:

i.p.; daily; 5 weeks
Result:

Reduced postprandial fasting glucose levels by 17.2% after 2 weeks and 40.0% after 5 weeks; reduced insulin levels by 23.2% after 5 weeks; reduced plasma FFA levels by 34.7% after 5 weeks compared to vehicle controls; improved glucose disposal during GTT; enhanced exogenous-insulin-stimulated glucose uptake during ITT; significantly reduced water intake; reduced white adipose tissue adipocyte diameters; significantly increased mRNA expression of PPARγ and its target genes (Fabp4, Glut4, Fas); significantly reduced mRNA and protein levels of HSL; significantly increased insulin-stimulated Akt phosphorylation in white adipose tissue.

Animal Model:

C57BL/6J (male, 5-6 weeks old) injected with N-Butyl-N-(4-hydroxybutyl)nitrosamine^[6]
Dosage:

150 mg/kg/day
Administration:

oral via drinking water; daily; 20 weeks
Result:

Reduced the incidence of BBN-induced high-grade muscle-invasive bladder cancer from 100% (12/12 mice) to 16.7% (2/12 mice); caused 7 cases of papillomas and 3 cases of low-grade non-muscle-invasive bladder cancer in treated mice; up-regulated FOXO1 protein expression and down-regulated MMP-2 protein expression in mouse bladder tissues.

化学情報

CAS 番号 32507-66-7
性状 Solid
分子量 258.27
分子式 C₁₅H₁₄O₄
Color White to yellow
SMILES

OC1=CC(O)=CC(/C=C/C2=CC(OC)=C(O)C=C2)=C1
Structure Classification
- Phenols
- Polyphenols
- Stilbenes
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (4)

All Cell Proliferation/Viability AssayRT-PCRIn Vivo Efficacy StudyHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Int Immunopharmacol

Isorhapontigenin suppresses inflammation, proliferation and aggressiveness of rheumatoid arthritis fibroblast-like synoviocytes by targeting farnesyl diphosphate synthase. [Abstract]

2025 May 23:159:114894. PMID: 40412131
Int Immunopharmacol

Isorhapontigenin delays senescence and matrix degradation of nucleus pulposus cells via PI3K/AKT/mTOR-mediated autophagy pathway in vitro and alleviates intervertebral disc degeneration in vivo. [Abstract]

2024 Jul 26:139:112717. PMID: 39067404
mSphere

Exploring the potential of isorhapontigenin: attenuating Staphylococcus aureus virulence through MgrA-mediated regulation. [Abstract]

2024 Jun 5:e0031724. PMID: 38837389

Isorhapontigenin purchased from MedChemExpress. Usage Cited in: mSphere. 2024 Jun 5:e0031724. [Abstract]

Cell viability of BEAS-2B and L-02 cell lines after 24-h exposure to various concentrations of Isorhapontigenin (0, 1, 6.25, 12.5, 25, 50, 100 μM).

Isorhapontigenin purchased from MedChemExpress. Usage Cited in: mSphere. 2024 Jun 5:e0031724. [Abstract]

RT-qPCR analysis of the effect of Isorhapontigenin (ISO) (1, 25, 50 μM) on the expression of the hla gene.

Isorhapontigenin purchased from MedChemExpress. Usage Cited in: mSphere. 2024 Jun 5:e0031724. [Abstract]

The impact of Isorhapontigenin (ISO) (20 mg/kg, s.c.) on survival rates of mice infected with a lethal dose of S. aureus Newman.

Isorhapontigenin purchased from MedChemExpress. Usage Cited in: mSphere. 2024 Jun 5:e0031724. [Abstract]

Histological analysis of the impact of Isorhapontigenin (ISO) (20 mg/kg, s.c.) on the lungs of mice, using H&E staining.

Isorhapontigenin purchased from MedChemExpress. Usage Cited in: mSphere. 2024 Jun 5:e0031724. [Abstract]

Western blot analysis of the impact of Isorhapontigenin ISO (1, 25, 50 μM) on the production of α-hemolysin.
Biomed Res Int

Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPAR α/ γ-AMPK-SIRT1 Pathway and Fatty Acid Metabolism. [Abstract]

2021 Sep 9;2021:9066938. PMID: 34540999

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (193.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8719 mL

19.3596 mL

38.7192 mL

5 mM

0.7744 mL

3.8719 mL

7.7438 mL

10 mM

0.3872 mL

1.9360 mL

3.8719 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (9.68 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (295 KB)
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Liang Y, et al. SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers. Autophagy. 2016;12(8):1229-1239. [Content Brief]

[2]. Zha H, et al. Isorhapontigenin alleviates acetaminophen-induced liver injury by promoting fatty acid oxidation. Biochim Biophys Acta Mol Basis Dis. 2025;1871(2):167575. [Content Brief]

[3]. Yeo SCM, et al. Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. Br J Pharmacol. 2017;174(13):2043-2059. [Content Brief]

[4]. Yao P, et al. Isorhapontigenin alleviates lipopolysaccharide-induced acute lung injury via modulating Nrf2 signaling. Respir Physiol Neurobiol. 2021;289:103667. [Content Brief]

[5]. Chu XY, et al. Isorhapontigenin Improves Diabetes in Mice via Regulating the Activity and Stability of PPARγ in Adipocytes. J Agric Food Chem. 2020;68(13):3976-3985. [Content Brief]

[6]. Jiang G, et al. Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila). 2016 Jul;9(7):567-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8719 mL	19.3596 mL	38.7192 mL	96.7979 mL
	5 mM	0.7744 mL	3.8719 mL	7.7438 mL	19.3596 mL
	10 mM	0.3872 mL	1.9360 mL	3.8719 mL	9.6798 mL
	15 mM	0.2581 mL	1.2906 mL	2.5813 mL	6.4532 mL
	20 mM	0.1936 mL	0.9680 mL	1.9360 mL	4.8399 mL
	25 mM	0.1549 mL	0.7744 mL	1.5488 mL	3.8719 mL
	30 mM	0.1291 mL	0.6453 mL	1.2906 mL	3.2266 mL
	40 mM	0.0968 mL	0.4840 mL	0.9680 mL	2.4199 mL
	50 mM	0.0774 mL	0.3872 mL	0.7744 mL	1.9360 mL
	60 mM	0.0645 mL	0.3227 mL	0.6453 mL	1.6133 mL
	80 mM	0.0484 mL	0.2420 mL	0.4840 mL	1.2100 mL
	100 mM	0.0387 mL	0.1936 mL	0.3872 mL	0.9680 mL

Isorhapontigenin

4 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Isorhapontigenin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Isorhapontigenin

NF-κB アイソフォーム固有の製品をすべて表示